Rapport Therapeutics Q3 2026 earnings

RAPP · 2026-10-30 17:12 AMC ET · 8-K on SEC

Net loss widened to $56.6 million as R&D expenses increased to $51.4 million, though cash position remained strong at $436.1 million.

Headline numbers

MetricActualYoYQoQ8-K location
EPS (GAAP)-$1.19+59%—Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $60.8 million (+106% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge not stated in the 8-K

KPIs

not stated in the 8-K

Guidance

not stated in the 8-K

What drove it

  • Revenue story No revenue reported; company is clinical-stage.
  • EPS story Net loss per share widened to -$1.19 driven by higher operating expenses.
  • One-off check not stated in the 8-K

The good

  • Cash position of $436.1 million expected to fund operations into the second half of 2029

The bad

  • Net loss widened to $56.6 million (+112% YoY)
  • R&D expenses increased to $51.4 million (+127% YoY)
  • SG&A expenses increased to $9.4 million (+38% YoY)

The ugly

  • none

Open questions

  • No Q3 financial results were provided in the filing; only a business update was attached.
Full release

Rapport Therapeutics (RAPP) earnings release, October 30, 2026

Rapport Therapeutics, Inc. (RAPP) · Form 8-K, Item 2.02 · Filed · SEC filing

No press release attached to this 8-K.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Rapport Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.